Back to top
more

KALEIDO BIOSCI (KLDO)

(Delayed Data from NSDQ)

$14.45 USD

14.45
10,764

+0.15 (1.05%)

Updated May 3, 2019 04:00 PM ET

After-Market: $14.25 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Exelixis (EXEL) Initiates Early Stage Study of Lymphoma

by Zacks Equity Research

Exelixis (EXEL) commences the dose-escalation stage of the phase I study of XL114 in patients with non-Hodgkin's lymphoma.

Vertex's (VRTX) Pain Candidate Meets Goal in Two Studies

by Zacks Equity Research

Vertex's (VRTX) two phase II proof-of-concept studies evaluating VX-548 for acute pain following abdominoplasty surgery or bunionectomy surgery meets the primary endpoint.

Novartis (NVS) Beovu Gets Label Expansion for DME in EU

by Zacks Equity Research

Novartis (NVS) ophthalmology drug Beovus label gets expanded in EU for diabetic macular edema.

Dare Bioscience, Inc. (DARE) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Dare Bioscience, Inc. (DARE) delivered earnings and revenue surprises of 14.29% and 100%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Roche (RHHBY) Late-Stage Study for ES-SCLC Fails to Meet Goal

by Zacks Equity Research

Roche (RHHBY) phase III SKYSCRAPER-02 study assessing tiragolumab plus Tecentriq and chemotherapy as a first-line treatment for extensive-stage small cell lung cancer did not meet co-primary endpoint of progression-free survival.

Bristol Myers (BMY) Application for Opdivo With Chemo Validated

by Zacks Equity Research

Bristol Myers (BMY) type II variation application for Opdivo in combination with chemotherapy for the neoadjuvant treatment of patients with non-small cell lung cancer gets EMA validation.

Novartis (NVS) Gets Positive CHMP Opinion for Jakafi, Kymriah

by Zacks Equity Research

Novartis (NVS) obtains positive CHMP opinion for the label expansion of Jakafi and Kymriah.

Blueprint Medicines (BPMC) Gets EU Nod for Ayvakyt in SM

by Zacks Equity Research

The European Commission approves Blueprint Medicines' (BPMC) Ayvakyt for treating adult patients with advanced systemic mastocytosis.

Bristol (BMY) Label Expansion of Reblozyl Delayed by 3 Months

by Zacks Equity Research

Bristol Myers (BMY) application seeking label expansion of Reblozy extended by three months by the FDA.

Bristol Myers (BMY) Gains 16% YTD: Will the Momentum Continue?

by Zacks Equity Research

Bristol Myers (BMY) has put up an impressive performance so far in 2022, and the momentum should continue.

Rezolute (RZLT) Posts Positive Data From Congenital HI Study

by Zacks Equity Research

Rezolute (RZLT) releases favorable data from the phase IIb RIZE study on its lead candidate RZ358, currently being investigated for congenital hyperinsulinism.

ORIC Stock Plunges on Discontinuation of Oncology Candidate

by Zacks Equity Research

ORIC declines on discontinuation of pipeline candidate ORIC-101 following planned interim analyses of two phase Ib studies.

Vallon (VLON) Plummets as ADAIR Study Misses Primary Goal

by Zacks Equity Research

Vallon Pharmaceuticals (VLON) down as SEAL study evaluating lead investigational product candidate, ADAIR, fails to meet its primary endpoint.

Bristol Myers' (BMY) Opdualag Wins FDA Nod for Melanoma

by Zacks Equity Research

Bristol Myers (BMY) gets FDA approval for a fixed-dose combination of Opdivo (nivolumab) and relatlimab to treat patients 12 years of age or older with unresectable or metastatic melanoma.

Adagene (ADAG) Gets FDA Nod for Cancer Study on ADG126 Combo

by Zacks Equity Research

The FDA grants clearance to Adagene (ADAG) to begin clinical studies on its anti-CTLA-4 mAb, ADG126 in combination with pembrolizumab to treat advanced/metastatic solid tumors.

Catalyst (CPRX) Q4 Earnings Lag Estimates, Revenues Rise Y/Y

by Zacks Equity Research

Catalyst's (CPRX) fourth-quarter 2021 earnings miss estimates while revenues slightly beat the mark.

Epizyme (EPZM) Down More Than 50% in Past 3 Months: Here's Why

by Zacks Equity Research

Epizyme's (EPZM) lead drug, Tazverik, is approved to treat follicular lymphoma and epithelioid sarcoma in the United States. Stiff competition in the target remains an overhang.

Adicet Bio, Inc. (ACET) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Adicet Bio, Inc. (ACET) delivered earnings and revenue surprises of -6.82% and 17.59%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

AnaptysBio's (ANAB) Acne Study on Imsidolimab Fails to Meet Goal

by Zacks Equity Research

AnaptysBio's (ANAB) phase II study evaluating imsidolimab for treating moderate-to-severe acne, fails to show improvement over placebo in top-line primary or secondary endpoints. Shares down.

Acadia (ACAD) Stock Up on FDA's Action Date for Nuplazid sNDA

by Zacks Equity Research

Acadia (ACAD) gets an action date of Aug 4, 2022, from the FDA for its resubmitted sNDA for pimavanserin to treat hallucinations and delusions associated with Alzheimer's disease psychosis.

Horizon's (HZNP) sBLA for Krystexxa Gets FDA Priority Review

by Zacks Equity Research

The FDA grants priority review to Horizon's (HZNP) sBLA for Krystexxa plus methotrexate to treat people living with uncontrolled gout. A decision is due on Jul 7, 2022.

FDA Nods to Bristol Myers' (BMY) Opdivo for Additional Indication

by Zacks Equity Research

Bristol Myers' (BMY) immuno-oncology Opdivo gets FDA nod for adult patients with resectable non-small cell lung cancer in the neoadjuvant setting in combination with platinum-doublet chemotherapy.

Horizon (HZNP) Q4 Earnings Beat Estimates, Revenues Rise Y/Y

by Zacks Equity Research

Horizon's (HZNP) revenues beat estimates in the fourth quarter of 2021. Shares rise following the results.

Acadia (ACAD) Q4 Earnings & Revenues Fall Shy of Estimates

by Zacks Equity Research

Acadia (ACAD) posts a wider-than-expected loss for the fourth quarter of 2021. Shares fall during the after-hours trading.

    Apellis (APLS) Q4 Loss Widens, Revenues Surpass Estimates

    by Zacks Equity Research

    Apellis' (APLS) earnings miss estimates in the fourth quarter of 2021, while revenues surpass expectations.